Outro, a company focused on safe deprescribing, has raised $7 million in new funding. The round included participation from Listen Ventures, Cake Ventures, Jason Calacanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group, and Pave Health Ventures.
Deprescribing is the process of gradually reducing or stopping medications under medical supervision, often to avoid unnecessary side effects or drug interactions. Outro’s platform is designed to support this process, giving patients and clinicians a more structured approach than simply stopping a drug on their own.
The funding will likely be used to expand the platform’s reach and further develop its tools. With this round, Outro joins a growing number of digital health companies addressing the risks of polypharmacy and the need for better medication management.